Penumbra Inc. (PEN)
Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner
Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention, justifying a Buy rating. First-mover advantage in intelligent thrombectomy, expanding European reimbursement, and an aging population create strong long-term growth tailwinds. Despite premium valuation multiples, PEN's innovation, ecosystem, and divestiture of non-core assets support its growth and margin expansion potential.
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
PEN Stock Rises Following the Launch of Ruby XL System
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
Here's Why Penumbra (PEN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Penumbra (PEN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Growth Investors Will Love Penumbra (PEN)
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO Jason Mills - EVP, Strategy Conference Call Participants Robbie Marcus - JPMorgan Lei Huang - Wells Fargo Pito Chickering - Deutsche Bank Macauley Kilbane - William Blair Bill Plovanic - Canaccord Travis Steed - Bank of America Ryan Zimmerman - BTIG Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Matthew O'Brien - Piper Sandler David Rescott - Baird Operator Good afternoon. My name is Tameka and I will be your conference operator today.
